Company: HCWB
Filing Date: 2025-04-28
Form Type: DRS
Source: 0000950123-25-003769
Chunk: 133

Company: HCW Biologics Inc.
Filing Date: 2025-04-28
Form: DRS
Chunk 133
---
W Biologics Inc. Pursuant to 17 C.F.R. Section 200.83 Warrants, and (2) by Square Gate of the Commitment Shares and shares of our Common Stock that may be issued to Square Gate pursuant to the ELOC Purchase Agreement, which Registration Statement became effective on April 16, 2025. Item 16. Exhibits. The exhibits to this registration statement are listed in the Exhibit Index to this registration statement, which immediately precedes the Signature Page, and which Exhibit Index is hereby incorporated by reference. Item 17. Undertakings. The undersigned registrant hereby undertakes:

| (1) | to file, during any period in which offers or sales are being made, a post-effective amendment to this 
 registration statement:                                                                                |

| (i) | to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the 
 “Securities Act”);                                                                                    |

| (ii) | to reflect in the prospectus any facts or events arising after the effective date of the registration statement                                                                                                                                         
 (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in    
 volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus 
 filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in         
 the effective registration statement; and                                                                                                                                                                                                               |

| (iii) | to include any material information with respect to the plan of distribution not previously disclosed in the                                                                                                                                   
 registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (i), (ii) and (iii) do not apply if the registration statement is on Form S-1 and the information required 
 to be included in a post- effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are  
 incorporated by reference in the registration statement, or is contained